Increased ELISA Signal Using Plasmonix QuantaWell Plates

RALEIGH, N.C. - March 14, 2014 - PRLog -- Major Increase in ELISA Signal Using Plasmonix QuantaWell™ Plates

(Raleigh, NC) -- ImmunoReagents, a manufacturer of high quality polyclonal antibodies and reagents used by researchers, pharmaceutical and biotechnology companies, has established that QuantaWell ELISA plates give superior signal sensitivity over traditional 96-well fluorescent plates.

ImmunoReagents conducted an independent validation of Plasmonix QuantaWell 96-well ELISA plates and found that the new nanotechnology plates gave a remarkable improvement over the current Greiner Fluotrac 600 plates. "I was not expecting this much of an improvement over traditional plates. This is a game changer for those researchers looking for signal improvement." said Brad Heidinger, COO of ImmunoReagents."

“When we need an assay that has great sensitivity with a low signal to noise ratio, I will certainly choose the QuantaWell plates. It only makes sense. I hope to show the advantages of this plate to other like-minded researchers.”

For a full report of the data please go to: https://drive.google.com/file/d/0B5iUN2j_5_gmT0xfZEIzcnJVQmc/edit?usp=sharing

About ImmunoReagents

ImmunoReagents is a leading global manufacturer of quality polyclonal antibodies used in research and in vitro diagnostics. They offer a wide range of secondary antibodies covering a broad spectrum of immunoglobulins from various species. Antibodies include various levels of cross species absorptions to provide high specificity. The Company also manufactures primary polyclonal antibodies to hormones, cancer markers, cardiac markers and serum proteins. In addition to its vast product lines, ImmunoReagents also provides custom manufacturing to meet specific customer requirements while adhering to cGMP guidelines and ISO quality systems requirements.

More information about ImmunoReagents: www.immunoreagents.com

About Plasmonix Inc.

Plasmonix’s focus is on the enhancement of luminescent signals through advanced use of nanoparticles and the application of its technology in life science and diagnostic assays. Commercialization of other consumer and industrial applications, including cosmetics, apparel, paints, lighting, solar and communications, will be approached through partnerships and collaborations.

More information about Plasmonix: http://plasmonixinc.com/